Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 14/20 | 0.66 |
| ▸ | MMP2 | P08253 | 7/20 | 0.66 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 11/20 | 0.54 |
| ▸ | MMP8 | P22894 | 5/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 5/20 | 0.52 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.52 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323670 | 1.00 | MMP9 (0.66) | MMP9MMP2ADAMTS4MMP13MMP8 | |
| SCHEMBL6321598 | 0.89 | MMP9 (0.63) | MMP9MMP2ADAMTS4MMP13MMP8 | |
| SCHEMBL6321600 | 0.89 | MMP9 (0.63) | MMP9MMP2ADAMTS4MMP13MMP8 | |
| SCHEMBL5097962 | 0.86 | ADAMTS4 (0.77) | MMP9MMP2ADAMTS4MMP13MMP8 | |
| SCHEMBL11956306 | 0.86 | ADAMTS4 (0.77) | MMP9MMP2ADAMTS4MMP13MMP8 | |
| SCHEMBL6324153 | 0.86 | TAS2R14 (0.61) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL6325795 | 0.86 | TAS2R14 (0.61) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL6324157 | 0.86 | TAS2R14 (0.61) | MMP9MMP2MMP13MMP8ALDH1A1 | |
| SCHEMBL6326216 | 0.86 | MMP9 (0.62) | MMP9MMP2ADAMTS4MMP13MMP8 | |
| Hydrochloric Acid SCHEMBL7347875 | 0.85 | ADAMTS4 (0.76) | MMP9MMP2ADAMTS4MMP13MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | MMP9 11/4885MMP2 26/4885ADAMTS4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.